Review Article
Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis
Table 3
Plasma fibrinogen according to clinicopathological features.
| | Outcome of interest | Studies () | Patients | OR | 95% CI | value | Model | , , value |
| | T3-T4 versus T1-T2 | 3 | 2217 | 3.69 | 1.81–7.54 | 0.0003 | Random | 6.39, 69%, 0.04 | | G3-G4 versus G1-G2 | 3 | 2217 | 2.04 | 1.68–2.48 | 0.000 | Fixed | 3.91, 49%, 0.14 | | CcRCC versus non-ccRCC | 3 | 2217 | 0.79 | 0.62–1.01 | 0.06 | Fixed | 1.38, 0%, 0.06 | | Male versus female | 3 | 2217 | 0.86 | 0.70–1.05 | 0.14 | Fixed | 2.83, 29%, 0.24 |
|
|
CcRCC: clear cell renal cell carcinoma; Fixed: fixed, inverse variance model; : -squared; OR: odds ratio; Random: random, I–V heterogeneity model; RCC: renal cell carcinoma.
|
